FindMyKOL
Clinical trialNCT03556228RecruitingPhase 1/2Interventional

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

NCT03556228 is a phase 1/2 interventional trial sponsored by VM Oncology, LLC. As of 21 Nov 2026, it is recruiting participants. It studies 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab in Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy and 23 more conditions. The registry lists an enrollment of 242 participants at 13 sites in 2 countries. The registry lists a start date of 8 Jun 2018 and a primary completion date of 31 Dec 2027. 2 of its registered investigators have a FindMyKOL profile.

SponsorVM Oncology, LLCEnrollment242Adenoid Cystic CarcinomaAny Solid Tumors Progressed After a Prior ImmunotherapyEsophageal CancerHead and Neck CancersHead and Neck Cancers - NasopharyngealHead and Neck Cancers - Salivary Gland+19 more conditions
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03556228
FieldValue
Registry IDNCT03556228
StatusRecruiting
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorVM Oncology, LLC
Enrollment242
Registered sites13
Countries2
ConditionsAdenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Esophageal Cancer, Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Salivary Gland and 19 more conditions
Drugs4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab
Start8 Jun 2018
Primary completion31 Dec 2027
Study completion30 Jun 2028
Last update posted4 Nov 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site, 1 recruiting
  • Providence Medical Foundation (site 209)

    Santa Rosa

    Ian C Anderson, MD
    Recruiting
Connecticut, United States1 site, 1 recruiting
  • Hartford Hospital (site 210)

    Hartford

    Jaykumar Thumar, MD
    Recruiting
District of Columbia, United States1 site, 1 recruiting
  • the George Washington University Cancer Center (site 212)

    Washington D.C.

    Pavani Chalasani, MD, MPH
    Recruiting
Florida, United States2 sites, 2 recruiting
  • Holy Cross Hospital (site 213)

    Fort Lauderdale

    Georges Azzi, MD
    Recruiting
  • Memorial Cancer Institute at Memorial Healthcare Systems (site 132)

    Pembroke Pines

    Luis E Raez, MD
    Recruiting
New Jersey, United States3 sites, 3 recruiting
  • Englewood Hospital and Medical Center (site 202)

    Englewood

    Minaxi Jhawer, MD
    Recruiting
  • Summit Medical Group (site 205)

    Florham Park

    Steven Papish, MD, FACP
    Recruiting
  • Atlantic Health System, Morristown Medical Center (site 124)

    Morristown

    Angela Alistar, MD
    Recruiting
New Mexico, United States1 site, 1 recruiting
  • Presbyterian Kaseman Hospital (site 208)

    Albuquerque

    Ethan Binder, MD
    Recruiting
New York, United States1 site, 1 recruiting
  • Weill Cornell Medicine, Cornell University (site 126)

    New York

    Ashish Saxena, M.D., Ph.D.
    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • Cancer Care Associates of York (site 206)

    York

    Chanh Huynh, MD
    Recruiting
Texas, United States1 site, 1 recruiting
  • the University of Texas Md Anderson Cancer Center (site 127)

    Houston

    David S Hong, MD
    Recruiting
Puerto Rico1 site, 1 recruiting
  • Panoncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)

    San Juan

    Marcia Cruz-Correa, MD, PhD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 site, 1 recruitingNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvania: 1 site, 1 recruitingPA1New Jersey: 3 sites, 3 recruitingNJ3Connecticut: 1 site, 1 recruitingCT1California: 1 site, 1 recruitingCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew Mexico: 1 site, 1 recruitingNM1OklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1Florida: 2 sites, 2 recruitingFL2District of Columbia: 1 site, 1 recruitingDC1
Fewer sitesMore sites

Outside the United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03556228

Each answer restates registry values shown on this page.

What is NCT03556228?

NCT03556228 is a phase 1/2 interventional trial sponsored by VM Oncology, LLC. It studies 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab in Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy and 23 more conditions.

Is NCT03556228 recruiting?

As of 21 Nov 2026, it is recruiting participants. 13 of its 13 sites list their own status as recruiting.

Who leads NCT03556228?

The registry names Clinical Development (study chair, VM Oncology) as the overall official.

Where does NCT03556228 run?

The registry lists 13 sites in 2 countries. Most sites are in these countries: United States (12) and Puerto Rico (1).

Which drugs does NCT03556228 study?

The registered drug and biological interventions are 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab.

When is NCT03556228 expected to complete?

The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 30 Jun 2028. The sponsor last updated the record on 4 Nov 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.